A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.

<h4>Background</h4>Chronic kidney disease (CKD) is a common and costly condition to treat. Economic evaluations of health care often incorporate patient preferences for health outcomes using utilities. The objective of this study was to determine pooled utility-based quality of life (the...

Full description

Saved in:
Bibliographic Details
Main Authors: Melanie Wyld, Rachael Lisa Morton, Andrew Hayen, Kirsten Howard, Angela Claire Webster
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS Medicine
Online Access:https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1001307&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849434080146358272
author Melanie Wyld
Rachael Lisa Morton
Andrew Hayen
Kirsten Howard
Angela Claire Webster
author_facet Melanie Wyld
Rachael Lisa Morton
Andrew Hayen
Kirsten Howard
Angela Claire Webster
author_sort Melanie Wyld
collection DOAJ
description <h4>Background</h4>Chronic kidney disease (CKD) is a common and costly condition to treat. Economic evaluations of health care often incorporate patient preferences for health outcomes using utilities. The objective of this study was to determine pooled utility-based quality of life (the numerical value attached to the strength of an individual's preference for a specific health outcome) by CKD treatment modality.<h4>Methods and findings</h4>We conducted a systematic review, meta-analysis, and meta-regression of peer-reviewed published articles and of PhD dissertations published through 1 December 2010 that reported utility-based quality of life (utility) for adults with late-stage CKD. Studies reporting utilities by proxy (e.g., reported by a patient's doctor or family member) were excluded. In total, 190 studies reporting 326 utilities from over 56,000 patients were analysed. There were 25 utilities from pre-treatment CKD patients, 226 from dialysis patients (haemodialysis, n = 163; peritoneal dialysis, n = 44), 66 from kidney transplant patients, and three from patients treated with non-dialytic conservative care. Using time tradeoff as a referent instrument, kidney transplant recipients had a mean utility of 0.82 (95% CI: 0.74, 0.90). The mean utility was comparable in pre-treatment CKD patients (difference  =  -0.02; 95% CI: -0.09, 0.04), 0.11 lower in dialysis patients (95% CI: -0.15, -0.08), and 0.2 lower in conservative care patients (95% CI: -0.38, -0.01). Patients treated with automated peritoneal dialysis had a significantly higher mean utility (0.80) than those on continuous ambulatory peritoneal dialysis (0.72; p = 0.02). The mean utility of transplant patients increased over time, from 0.66 in the 1980s to 0.85 in the 2000s, an increase of 0.19 (95% CI: 0.11, 0.26). Utility varied by elicitation instrument, with standard gamble producing the highest estimates, and the SF-6D by Brazier et al., University of Sheffield, producing the lowest estimates. The main limitations of this study were that treatment assignments were not random, that only transplant had longitudinal data available, and that we calculated EuroQol Group EQ-5D scores from SF-36 and SF-12 health survey data, and therefore the algorithms may not reflect EQ-5D scores measured directly.<h4>Conclusions</h4>For patients with late-stage CKD, treatment with dialysis is associated with a significant decrement in quality of life compared to treatment with kidney transplantation. These findings provide evidence-based utility estimates to inform economic evaluations of kidney therapies, useful for policy makers and in individual treatment discussions with CKD patients.
format Article
id doaj-art-b7421841ca674efba2827d510cbbdb67
institution Kabale University
issn 1549-1277
1549-1676
language English
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Medicine
spelling doaj-art-b7421841ca674efba2827d510cbbdb672025-08-20T03:26:48ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762012-01-0199e100130710.1371/journal.pmed.1001307A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.Melanie WyldRachael Lisa MortonAndrew HayenKirsten HowardAngela Claire Webster<h4>Background</h4>Chronic kidney disease (CKD) is a common and costly condition to treat. Economic evaluations of health care often incorporate patient preferences for health outcomes using utilities. The objective of this study was to determine pooled utility-based quality of life (the numerical value attached to the strength of an individual's preference for a specific health outcome) by CKD treatment modality.<h4>Methods and findings</h4>We conducted a systematic review, meta-analysis, and meta-regression of peer-reviewed published articles and of PhD dissertations published through 1 December 2010 that reported utility-based quality of life (utility) for adults with late-stage CKD. Studies reporting utilities by proxy (e.g., reported by a patient's doctor or family member) were excluded. In total, 190 studies reporting 326 utilities from over 56,000 patients were analysed. There were 25 utilities from pre-treatment CKD patients, 226 from dialysis patients (haemodialysis, n = 163; peritoneal dialysis, n = 44), 66 from kidney transplant patients, and three from patients treated with non-dialytic conservative care. Using time tradeoff as a referent instrument, kidney transplant recipients had a mean utility of 0.82 (95% CI: 0.74, 0.90). The mean utility was comparable in pre-treatment CKD patients (difference  =  -0.02; 95% CI: -0.09, 0.04), 0.11 lower in dialysis patients (95% CI: -0.15, -0.08), and 0.2 lower in conservative care patients (95% CI: -0.38, -0.01). Patients treated with automated peritoneal dialysis had a significantly higher mean utility (0.80) than those on continuous ambulatory peritoneal dialysis (0.72; p = 0.02). The mean utility of transplant patients increased over time, from 0.66 in the 1980s to 0.85 in the 2000s, an increase of 0.19 (95% CI: 0.11, 0.26). Utility varied by elicitation instrument, with standard gamble producing the highest estimates, and the SF-6D by Brazier et al., University of Sheffield, producing the lowest estimates. The main limitations of this study were that treatment assignments were not random, that only transplant had longitudinal data available, and that we calculated EuroQol Group EQ-5D scores from SF-36 and SF-12 health survey data, and therefore the algorithms may not reflect EQ-5D scores measured directly.<h4>Conclusions</h4>For patients with late-stage CKD, treatment with dialysis is associated with a significant decrement in quality of life compared to treatment with kidney transplantation. These findings provide evidence-based utility estimates to inform economic evaluations of kidney therapies, useful for policy makers and in individual treatment discussions with CKD patients.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1001307&type=printable
spellingShingle Melanie Wyld
Rachael Lisa Morton
Andrew Hayen
Kirsten Howard
Angela Claire Webster
A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.
PLoS Medicine
title A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.
title_full A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.
title_fullStr A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.
title_full_unstemmed A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.
title_short A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments.
title_sort systematic review and meta analysis of utility based quality of life in chronic kidney disease treatments
url https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1001307&type=printable
work_keys_str_mv AT melaniewyld asystematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT rachaellisamorton asystematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT andrewhayen asystematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT kirstenhoward asystematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT angelaclairewebster asystematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT melaniewyld systematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT rachaellisamorton systematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT andrewhayen systematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT kirstenhoward systematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments
AT angelaclairewebster systematicreviewandmetaanalysisofutilitybasedqualityoflifeinchronickidneydiseasetreatments